Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.
2.

5alpha-reductase isoenzymes 1 and 2 in the rat testis during postnatal development.

Killian J, Pratis K, Clifton RJ, Stanton PG, Robertson DM, O'Donnell L.

Biol Reprod. 2003 May;68(5):1711-8. Epub 2002 Dec 11.

PMID:
12606426
3.

Different patterns of 5alpha-reductase expression, cellular distribution, and testosterone metabolism in human follicular dermal papilla cells.

Liu S, Yamauchi H.

Biochem Biophys Res Commun. 2008 Apr 18;368(4):858-64. doi: 10.1016/j.bbrc.2008.01.130. Epub 2008 Feb 5.

PMID:
18258185
4.

Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer.

Thomas LN, Douglas RC, Lazier CB, Too CK, Rittmaster RS, Tindall DJ.

Eur Urol. 2008 Feb;53(2):244-52. Epub 2007 Nov 5. Review.

PMID:
18006217
5.

Differential regulation of rat testicular 5alpha-reductase type 1 and 2 isoforms by testosterone and FSH.

Pratis K, O'Donnell L, Ooi GT, Stanton PG, McLachlan RI, Robertson DM.

J Endocrinol. 2003 Mar;176(3):393-403.

6.

5alpha-reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium.

Thomas LN, Douglas RC, Vessey JP, Gupta R, Fontaine D, Norman RW, Thompson IM, Troyer DA, Rittmaster RS, Lazier CB.

J Urol. 2003 Nov;170(5):2019-25.

PMID:
14532845
7.
8.

Enzyme assay for 5alpha-reductase type 2 activity in the presence of 5alpha-reductase type 1 activity in rat testis.

Pratis K, O'Donnell L, Ooi GT, McLachlan RI, Robertson DM.

J Steroid Biochem Mol Biol. 2000 Dec 1;75(1):75-82.

PMID:
11179911
9.

Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.

Lazier CB, Thomas LN, Douglas RC, Vessey JP, Rittmaster RS.

Prostate. 2004 Feb 1;58(2):130-44.

PMID:
14716738
10.

Inhibitory activities of some traditional Chinese herbs against testosterone 5α-reductase and effects of Cacumen platycladi on hair re-growth in testosterone-treated mice.

Zhang B, Zhang RW, Yin XQ, Lao ZZ, Zhang Z, Wu QG, Yu LW, Lai XP, Wan YH, Li G.

J Ethnopharmacol. 2016 Jan 11;177:1-9. doi: 10.1016/j.jep.2015.11.012. Epub 2015 Nov 11.

PMID:
26571086
11.

5-alpha-reductase and the development of the human prostate.

Radmayr C, Lunacek A, Schwentner C, Oswald J, Klocker H, Bartsch G.

Indian J Urol. 2008 Jul;24(3):309-12. doi: 10.4103/0970-1591.42610.

12.

Androgen-induced prostate-specific antigen gene expression is mediated via dihydrotestosterone in LNCaP cells.

Zhu YS, Cai LQ, You X, Cordero JJ, Huang Y, Imperato-McGinley J.

J Androl. 2003 Sep-Oct;24(5):681-7.

13.

Saturable binding of finasteride to steroid 5alpha-reductase as determinant of nonlinear pharmacokinetics.

Suzuki R, Satoh H, Ohtani H, Hori S, Sawada Y.

Drug Metab Pharmacokinet. 2010;25(2):208-13.

14.

Benzo[c]quinolizin-3-ones: a novel class of potent and selective nonsteroidal inhibitors of human steroid 5alpha-reductase 1.

Guarna A, Machetti F, Occhiato EG, Scarpi D, Comerci A, Danza G, Mancina R, Serio M, Hardy K.

J Med Chem. 2000 Oct 5;43(20):3718-35.

PMID:
11020287
15.

Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.

Bartsch G, Rittmaster RS, Klocker H.

World J Urol. 2002 Apr;19(6):413-25. Review.

PMID:
12022710
16.

19-nor-10-azasteroids: a novel class of inhibitors for human steroid 5alpha-reductases 1 and 2.

Guarna A, Belle C, Machetti F, Occhiato EG, Payne AH, Cassiani C, Comerci A, Danza G, De Bellis A, Dini S, Marrucci A, Serio M.

J Med Chem. 1997 Mar 28;40(7):1112-29.

PMID:
9089333
17.

Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer.

Thomas LN, Lazier CB, Gupta R, Norman RW, Troyer DA, O'Brien SP, Rittmaster RS.

Prostate. 2005 May 15;63(3):231-9.

PMID:
15538746
18.

Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer.

Andriole GL, Humphrey P, Ray P, Gleave ME, Trachtenberg J, Thomas LN, Lazier CB, Rittmaster RS.

J Urol. 2004 Sep;172(3):915-9.

PMID:
15310997
19.

The loss of 5alpha-reductase type I and type II mRNA expression in metastatic prostate cancer to bone and lymph node metastasis.

Habib FK, Ross M, Bayne CW, Bollina P, Grigor K, Chapman K.

Clin Cancer Res. 2003 May;9(5):1815-9.

20.

Supplemental Content

Support Center